Firm negotiates exclusive license to NLC technology from PharmaSol.

Brookwood Pharmaceuticals, a subsidiary of SurModics, has obtained exclusive rights to all pharmaceutical applications of lipid nanoparticle technology from PharmaSol.

According to the companies, the PharmaSol technology can be used to formulate drugs into nanostructured lipid carriers (NLCs™), which offer a number of advantages over other drug delivery nanotechnologies, including increased drug loading, improved drug incorporation and the ability to produce suspensions of higher solids content.

Brookwood is currently offering this technology to potential customers, while also generating additional data to accelerate product development of the NLC drug delivery platform.


Previous articleNo soup for you (no more) – VC-backed companies shooting for SBIR eligibility
Next articleDynPort Vaccine Lands $32.3M NIAID Contract